Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06058702 · ClinicalTrials.gov registry record · Phase 1
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
A Phase 1 study of Schizophrenia and Cannabis Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 215
- Enrollment target
- 1
- Study location
NCT06058702: Recruiting Phase 1 study of Schizophrenia and Cannabis Use Disorder, sponsored by Yale University.
NCT06058702 is a Phase 1 study of Schizophrenia and Cannabis Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 215 participants, roughly in line with the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06058702, a Phase 1 study of Schizophrenia and Cannabis Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 215 participants
- Enrollment target
- 1
- Study location
Study Summary
Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher potency of cannabis, the availability of highly potent cannabinoid products, the commercialization of cannabis, and the rising rates of cannabis use, it is critical to understand how genetic factors influence 1) an individual's vulnerability for addiction and psychosis, 2) the response to cannabinoids, 3) the response to novel treatments for CanUD. CanUD is strongly genetically influenced; the investigators published the first CanUD genomewide association study (GWAS) with genomewide-significant results; however, the precise nature of the contribution of genetic factors in the development of CanUD is still not clear. Cannabis exposure has also been linked to a number of psychosis outcomes including schizophrenia (SCZ). SCZ is highly heritable and population-based and genetics studies both support a bidirectional genetic relationship between SCZ and CanUD. However, the precise contribution of genetic factors in the development of psychosis outcomes related to cannabis are not clear.
Primary Outcome
The VAS is a scale to document perceived reward. A higher score reflects a positive response.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Delta-9-THC Medium Dose
- DRUG Delta-9-THC Very Low Dose
Study Locations (1)
Connecticut
- West Haven Veterans Affairs Medical Center - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT06058702 shows while recruiting
NCT06058702 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06058702 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06058702 about?
NCT06058702 is a clinical study titled "Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans". Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher potenc...
What is the current status of trial NCT06058702?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 215 participants. The study started on 2024-09-16. Estimated completion is 2028-12-31.
What conditions does trial NCT06058702 study?
This clinical trial studies the following conditions: Schizophrenia, Cannabis Use Disorder.
What interventions are being tested in trial NCT06058702?
The interventions under investigation include: Placebo (DRUG), Delta-9-THC Medium Dose (DRUG), Delta-9-THC Very Low Dose (DRUG).
Who is sponsoring clinical trial NCT06058702?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06058702 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06058702's enrollment target sits among peer trials
215 84th of 315 higher than 232 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI